Bondi's DOJ Day 1 directives: Fight weaponization of justice, eliminate cartels, lift death penalty ban
EXCLUSIVE: Attorney General Pam Bondi will issue several major directives on her first day leading the Justice Department, including orders to combat the weaponization of the legal system; make prosecutors seek the death penalty when appropriate; and work with the Department of Homeland Security to "completely eliminate" cartels and transnational criminal organizations, Fox News Digital has learned.
Bondi was confirmed by the Senate Monday night as attorney general of the United States and was sworn in on Tuesday.
Fox News Digital exclusively obtained memos outlining Bondi's first-day directives, which will lay the groundwork for the Justice Department under her leadership.
Bondi issued a directive regarding "zealous advocacy." Bondi said DOJ attorneys' responsibilities include "aggressively enforcing criminal laws passed by Congress, but also vigorously defending presidential policies and actions on behalf of the United States against legal challenges."
"The discretion afforded Justice Department attorneys with respect to those responsibilities does not include latitude to substitute their personal political views or judgments for those that prevailed in the election," the memo states.
"When Justice Department attorneys refuse to faithfully carry out their role by, for example, refusing to advance good-faith arguments or declining to sign briefs, it undermines the constitutional order and deprives the President of the benefit of his lawyers," the memo continues.
Bondi, in the memo, states that "any Justice Department attorney who declines to sign a brief, refuses to advance good-faith arguments on behalf of the Trump administration, or otherwise delays or impedes the Justice Department's mission will be subject to discipline and potentially termination."
Bondi is set to establish the "Weaponization Working Group," which will review the activities of all law enforcement agencies over the past four years to identify instances of "politicized justice."
The working group's first reviews will include prosecutions against Trump led by former Special Counsel Jack Smith; Manhattan District Attorney Alvin Bragg; and the civil fraud case brought against Trump and his family by New York Attorney General Letitia James.
The working group will also review any potential prosecutorial abuse regarding Jan. 6, 2021; the FBI's targeting of Catholic Americans; the Justice Department's targeting of parents at school board meetings; and FACE Act abuses.
Meanwhile, Bondi also will end the moratorium on federal executions and order that federal prosecutors at the Department of Justice, including U.S. attorney's offices, seek the death penalty when appropriate —specifically with a focus on violent drug trafficking crimes.
Bondi also ordered that the Justice Department "re-evaluate instances of the prior administration electing not to seek the death penalty."
Bondi also is expected to rescind any DOJ policies that are "not sufficiently in line with President Trump's death penalty executive order."
The move represents a major reversal from the Justice Department's view of the death penalty under the Biden administration. In 2021, Biden allowed the DOJ to issue a moratorium on federal executions.
In December 2024, Biden commuted the sentences of 37 of the 40 criminals on federal death row, which President Donald Trump, in his executive order on the death penalty, described as the "most vile and sadistic rapists, child molesters, and murderers on Federal death."
Bondi said she is now also directing the Justice Department to achieve justice for the families of the victims of the 37 murderers that had their death sentences commuted.
As for cartels, Bondi is directing the Justice Department to work closely with the Department of Homeland Security and other federal partners to "completely eliminate" the threats of cartels and transnational criminal organizations.
Bondi plans to re-imagine charging priorities relating to those cases in order to ensure that law enforcement resources are focused on dismantling the foundational operational capacity of cartels, as opposed to just picking off low-level offenders.
Here, the Justice Department is expected to temporarily suspend some "bureaucratic approvals and reviews" in order to prioritize speedy prosecutions and captures of those accused of severe offenses like capital crimes, terrorism, or aiding the operations of cartels.
Bondi said Joint Task Force Vulcan, which was created to destroy MS-13, and Joint Task Force Alpha, which was created to fight human trafficking, would be "further empowered and elevated" to the Office of the Attorney General. Their missions are expected to expand—specifically Vulcan's—with a new focus on destroying Tren de Aragua.
Also on the cartel front, Bondi is directing the DOJ Office of Legal Policy to find legislative reforms to target equipment designed to make fentanyl pills and add Xylazine, a new deadly drug, to Schedule III of the Controlled Substances Act.
And as for illegal migrants, Bondi has directed the DOJ to pause all federal funding for sanctuary cities.
Bondi has also directed the DOJ to identify and evaluate all funding agreements with non-governmental organizations (NGOs) that provide support to illegal aliens.
She is also directing litigating components of the Justice Department to investigate instances of jurisdictions that are impeding law enforcement, and directing they be prosecuted, when necessary.
Meanwhile, Bondi will also create a new Joint Task Force on October 7 focused on holding Hamas accountable for its crimes against Jews during its terror attack in Israel on Oct. 7, 2023. The task force will also "achieve justice for victims and fight terrorist-led anti-Semitism."
The task force on Oct. 7 will pursue criminal charges where applicable against Hamas; seek the arrest and extradition of Hamas leadership; and investigate anti-Semitism in the United States.
Bondi is also directing the FBI to staff the joint task force with personnel "significantly experienced in investigating terrorism."
Beyond those directives, Bondi is directing the DOJ to confirm the termination of all Diversity, Equity and Inclusion (DEI) programs at the department by March 15. She also is demanding the removal of all references to DEI in training programs—specifically ending the emphasis on race and sex-based criteria and refocusing hiring and promotion guidelines "solely on merit."
Bondi will also work with the Department of Education to ensure that educational institutions receiving federal grants are adhering to "fair admission practices."
Bondi, a longtime prosecutor and former Florida attorney general, has vowed not to use her position to advance any political agenda, testifying to the Senate Judiciary Committee that "politics has to be taken out of this system."
Bondi told lawmakers in January that the "partisanship, the weaponization" at the Justice Department "will be gone."
"America will have one tier of justice for all," she said.
Before Bondi was confirmed, Fox News Digital exclusively reported that the Trump Justice Department fired more than a dozen key officials who worked on former Special Counsel Jack Smith's team prosecuting Trump, after Acting Attorney General James McHenry said they could not be trusted in "faithfully implementing the president's agenda."
And Friday, acting Deputy Attorney General Emil Bove issued a memo to the acting FBI director directing him to terminate eight FBI employees and identify all current and former bureau personnel assigned to Jan. 6 and Hamas cases for an internal review.
After the directive, on Tuesday, a group of nine FBI agents filed a lawsuit seeking to block the public identification of any FBI employees who worked on the Jan. 6 investigations into the U.S. Capitol riots in an attempt to head off what they described as potentially retaliatory efforts against personnel involved in the probe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
31 minutes ago
- Los Angeles Times
Court orders Trump administration to facilitate another deported man's return from El Salvador
WASHINGTON — A federal appeals court in New York on Tuesday ordered the Trump administration to facilitate the return of a man who was deported to El Salvador roughly 30 minutes after the court suspended an order to remove him from the U.S. The ruling in Jordin Alexander Melgar-Salmeron's case marks at least the fourth time this year that President Trump's administration has been ordered to facilitate the return of somebody mistakenly deported. The government said 'a confluence of administrative errors' led to Melgar-Salmeron's deportation on May 8, according to the decision by a three-judge panel from the 2nd U.S. Circuit Court of Appeals. The panel said administration officials must facilitate his return to the U.S. 'as soon as possible.' The judges gave them a week to identify his current physical location and custodial status and to specify what steps they will take to facilitate his return. Kilmar Abrego Garcia, whose mistaken deportation in March became a flashpoint in Trump's immigration crackdown, was returned from El Salvador this month to face human smuggling charges in Tennessee. In April, a Trump-nominated judge in Maryland ordered his administration to facilitate the return of a man who was deported to El Salvador in March despite having a pending asylum application. U.S. District Judge Stephanie Gallagher ruled that the government violated a 2019 settlement agreement when it deported the 20-year-old man, a Venezuelan native identified only as Cristian in court papers. And in May, another judge ordered the administration to facilitate the return of a Guatemalan man whom it deported to Mexico despite his fears of being harmed there. U.S. District Judge Brian Murphy found that the removal of the man, who is gay, likely 'lacked any semblance of due process.' Kunzelman writes for the Associated Press.
Yahoo
31 minutes ago
- Yahoo
China is a real threat to US biotech innovation: EY life science expert
China's growing biotech prowess has become a real threat to the industry in the US in recent years. Moves by the Trump administration could weaken the US market further, according to several experts watching the deals flowing into China, which amounted $30 billion in 2024 and are already more than half that total in mid-2025. EY life sciences leader Arda Ural is among those watching and said that China is no longer the land of generics and active pharmaceutical ingredients (APIs) used by the rest of the world. China has long been known as a "me too" producer — that is, a manufacturer of generics — as well as a source of APIs. But China is showing its might as it clinches more licensing deals for drugs developed domestically and increases clinical trials being conducted in the country. "The numbers are pretty compelling," Ural told Yahoo Finance. "A couple of years ago, we had pretty much no deals, or maybe under $1 billion in 2016. As of last year, there were $30 billion of licensing deals of Chinese assets into the US." But this didn't happen overnight. The Chinese Communist Party laid out a roadmap in 2015 that included investing in and growing the country's biotech sector. Ten years later, that is coming to fruition, Ural said. "That journey now is taking them upstream to more advanced innovation. Probably, we still have not seen first-in-class, but clearly they are going for best-in-class," Ural said. US companies buying or licensing products from China include a due diligence process, which can involve head-to-head comparisons to existing drugs or repeating clinical trials to ensure the data and efficacy results are accurate. This has helped ease concerns about intellectual property theft of US products, as well as concerns about data integrity in China. The prior doubts spurred the introduction of the Biosecure Act in Congress in 2023, which would prevent any entity receiving federal funds from using biotech equipment or services from "companies of concern." That bill has stalled in Congress. Meanwhile, the life sciences community continues to increase its interest in China. Companies like WuXi Biologics (WXXWY), WuXi AppTec (WUXAY), and BGI (formerly Beijing Genomics Institute) are among those under the spotlight. And during the pandemic, companies like CanSino ( which developed a vaccine, came into view. Now, with cuts to research funding in the US to the National Institutes of Health (NIH), as well as the loss of Food and Drug Administration staff, insiders are warning that China could fill the gaps and scoop up talent from the US. "The US still has the capacity to invest, but it is not, potentially, the only game in town," Ural said. He explained that China is still early in its journey, and while it does have government funding and Western-educated doctors and researchers, it doesn't have the type of firepower of US capital markets. "That is where they are lacking. There is no IPO market comparable to Western markets, there is no M&A exit strategy ... so that's the opportunity for them to come up," Ural said. A majority of the deals so far are US-based companies buying early-stage assets from Chinese company pipelines, bringing them to the US to validate and then produce and sell. At the same time, the US-based biotech industry has seen a slowdown in investment and IPO activity, and the NIH funding cuts by the Trump administration are exacerbating the dry spell. China's growth is also adding to the pressure since China is known for making things cheaper and faster than Western countries. Ural said that's why the partnership with US-based firms is a "winning strategy" for the overall industry. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices
New York Times
31 minutes ago
- New York Times
Trump Says He May Send Additional Patriot Systems to Ukraine
President Trump said Wednesday that he was weighing sending additional Patriot air defense systems to Ukraine amid intensifying Russian attacks. But it was not immediately clear whether Mr. Trump was considering donating the Patriots to Ukraine — as his predecessor, former President Joseph R. Biden Jr., and several European allies have done — or selling them to Kyiv. 'We're going to see if we can make some available,' Mr. Trump said during a news conference at the NATO summit in The Hague, where he held a nearly hourlong meeting with President Volodymyr Zelensky of Ukraine. But Mr. Trump cautioned that the systems, which Mr. Zelensky proposed buying directly in April, were 'very hard to get' and in limited supply, especially with the United States already providing some to Israel. Mr. Zelensky said in a statement that his meeting with Mr. Trump had been 'meaningful' and that the pair had discussed the prospects for a cease-fire. But neither he nor the White House offered details about how the meeting unfolded or whether it would lead additional American support. Mr. Zelensky has a complicated relationship with Mr. Trump, marked by meetings that have at times been tense and fraught, and at other times more substantive. His visit to the White House in February, where he was supposed to sign a landmark bilateral minerals deal, quickly unraveled as the two leaders publicly argued in the Oval Office. It took two more months for them to sit down together again, on the sidelines of Pope Francis' funeral in late April. That meeting helped defuse tensions between Kyiv and Washington and finalize the minerals deal. Want all of The Times? Subscribe.
